Prostate specific membrane antigen (PSMA) PET/CT for radiation planning and response assessment in intracranial high-grade gliomas
Open Access
- 8 January 2026
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Abstract
Background: Prostate-specific membrane antigen (PSMA) expression has been demonstrated in the tumor microenvironment of high-grade gliomas (HGG). Here, we assessed the utility of PSMA-positron emission tomography (PET) imaging in patients with HGG for radiation therapy (RT) planning and in differentiating tumor progression from post-treatment changes. Methods: Patients with HGG (WHO grade 3-4) were included in our prospective PET imaging registry. Analysis was stratified into two cohorts based on clinical indication for PET—Cohort A: RT planning; and Cohort B: evaluation of suspected recurrence. PSMA avidity was quantified using standardized uptake value (SUV) measurements including absolute maximum SUV(SUVmax), and SUV ratio referencing right parotid (SUVRp), and superior sagittal sinus (SUVRsss). Results: Twenty-seven patients were included (Cohort A, N = 19; Cohort B, N = 8). In Cohort A, all MRI T1 contrast-enhancing lesions were PET avid; with PSMA-avid volume exceeding MRI T1 contrast-enhancing volume in 4 patients (20%). The respective mean lesion SUVmax, SUVRp, and SUVRsss for patients with PSMA avid disease (n = 17) vs those without (n = 2) were 7.2 vs 1.5 (P = .002); 0.6 vs 0.2 (P = .008); and 6.5 vs 1.8 (P = .008). Post-RT mean SUVmax decreased by 25.8% (6.2 to 4.6, P = .005). In Cohort B, PSMA PET accurately identified pathologically confirmed tumor progression (n = 6, mean SUVmax 7.0) and necrosis (n = 1, SUVmax 1.5) in 88% patients. Conclusions: PSMA PET avidity, particularly SUVmax, is higher in glioblastoma multiforme (GBM) patients with residual tumor or tumor progression. These findings suggest a potential role for PSMA PET in tumor delineation, aiding in comprehensive coverage of tumor volumes for radiation planning and response assessment to differentiate tumor progression and post-treatment changes.Keywords
This publication has 32 references indexed in Scilit:
- PSMA radioligand uptake correlates with PSMA expression in high-grade glioma and brain metastasis: insights from a prospective PET-MRI guided multiregional biopsy studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- Comparative Analysis of Recurrent Glioblastoma Target Contours via 11C-Methionine, 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography, and Magnetic Resonance Imaging: Implications for Precision Radiotherapy PlanningAdvances in Radiation Oncology, 2024
- Additive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade GliomasPractical Radiation Oncology, 2024
- Imaging Glioblastoma PosttreatmentNeuroimaging Clinics Of North America, 2021
- Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617European Journal of Nuclear Medicine and Molecular Imaging, 2020
- Earliest radiological progression in glioblastoma by multidisciplinary consensus reviewJournal of Neuro-Oncology, 2018
- Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibodyJournal of Neuro-Oncology, 2018
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017
- Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscapeJournal of Neuro-Oncology, 2017
- Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical ProstatectomyEuropean Urology, 2016